Status:
COMPLETED
Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
Lead Sponsor:
Mirati Therapeutics Inc.
Conditions:
Advanced or Metastatic Solid Malignancies
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
A Study of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Advanced or Metastatic Malignancies
Detailed Description
Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that inhibits several closely related RTKs including the TAM family (Tyro3/Axl/MERTK), VEGFR2, KIT, and MET. The current ...
Eligibility Criteria
Inclusion
- Currently receiving sitravatinib single- agent or in combination with other therapeutic agent(s) in another Mirati- sponsored protocol
- Currently tolerating the treatment regimen in the parent protocol
- Experiencing clinical benefit with or without prior radiographic progression from the treatment regimen in the parent protocol in the opinion of the investigator and the investigator determines that continuing treatment is in the patient's best interest
Exclusion
- Known or suspected presence of other cancer
- Other life- threatening illness or organ system dysfunction compromising safety evaluation
Key Trial Info
Start Date :
June 29 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 25 2025
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT04887870
Start Date
June 29 2021
End Date
September 25 2025
Last Update
October 10 2025
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Rocky Mountain Cancer Centers - Littleton
Littleton, Colorado, United States, 80218
2
Local Institution - 516-014-029
Goshen, Indiana, United States, 46526
3
Local Institution - 516-014-002
Boston, Massachusetts, United States, 02215
4
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States, 48201